Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In the Original Investigation “Trends in Medicaid Reimbursements for Insulin From 1991 Through 2014,”1 published online August 24, 2015, and also in the October 2015 print issue of JAMA Internal Medicine, text in the Discussion section of the article has been reworded. The sentence “It is unlikely, however, that rebates would offset the increases in payments that we identified because Medicaid rebates for innovator drugs are statutorily capped at 23.1% of the average manufacturer price,” now reads, “It is unlikely, however, that rebates would offset the increases in payments that we identified because base Medicaid rebates for innovator drugs are the greater of 23.1% of the average manufacturer price (AMP) or the difference between AMP and the best price (the lowest price offered to any purchaser of that product, with a few exceptions, such as for drugs purchased by the Department of Veterans Affairs).”
Error in Text. JAMA Intern Med. 2016;176(3):417. doi:10.1001/jamainternmed.2015.8190